Physician profile
Stephen C Lobaugh
NPI 1336209840
$2,506.69
in general payments reported to CMS, 2019-2025
18 companies · $810 in 2025
The $810 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $145 · 2021: $175 · 2022: $311 · 2023: $472 · 2024: $339 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $370.17 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $312.79 | 2022-2025 | Infuse, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $261.45 | 2019-2023 | |
| Alcon Vision LLC | $249.95 | 2019-2025 | Eysuvis, Precision7, Total30 |
| Oyster Point Pharma, INC. | $190.43 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $181.61 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $153.78 | 2025 | |
| Coopervision INC. | $150.49 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.41 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $102.89 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $99.07 | 2021-2022 | |
| Allergan, INC. | $80.84 | 2019-2022 | |
| Sight Sciences, INC. | $79.02 | 2025 | Omni Surgical System |
| Abb Con-Cise Optical Group LLC | $52.55 | 2022-2023 | Spectacle Lenses, Contact Lens |
| Harrow Eye, LLC | $46.16 | 2025 | Vevye |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $31.65 | 2024 | Oxervate |
| Visioneering Technologies, INC. | $15.35 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lobaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.